CTTN Overexpression Confers Cancer Stem Cell-like Properties and Trastuzumab Resistance Via DKK-1/WNT Signaling in HER2 Positive Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Feb 25

PMID 36831511

Authors

So-Jeong Moon

Hyung-Jun Choi

Young-Hyeon Kye

Ga-Young Jeong

Hyung-Yong Kim

Jae-Kyung Myung

Gu Kong

Affiliations

Soon will be listed here.

Abstract

Background: Despite the therapeutic success of trastuzumab, HER2 positive (HER2+) breast cancer patients continue to face significant difficulties due to innate or acquired drug resistance. In this study we explored the potential role of CTTN in inducing trastuzumab resistance of HER2+ breast cancers.

Methods: Genetic changes of CTTN and survival of HER2+ breast cancer patients were analyzed in multiple breast cancer patient cohorts (METABRIC, TCGA, Kaplan-Meier (KM) plotter, and Hanyang University cohort). The effect of CTTN on cancer stem cell activity was assessed using the tumorsphere formation, ALDEFLUOR assay, and by in vivo xenograft experiments. CTTN-induced trastuzumab resistance was assessed by the sulforhodamine B (SRB) assay, colony formation assays, and in vivo xenograft model. RNA-seq analysis was used to clarify the mechanism of trastuzumab resistance conferred by CTTN.

Results: Survival analysis indicated that CTTN overexpression is related to a poor prognosis in HER2+ breast cancers (OS, = 0.05 in the Hanyang University cohort; OS, = 0.0014 in KM plotter; OS, = 0.008 and DFS, = 0.010 in METABRIC). CTTN overexpression-induced cancer stem cell-like characteristics in experiments of tumorsphere formation, ALDEFLUOR assays, and in vivo limiting dilution assays. CTTN overexpression resulted in trastuzumab resistance in SRB, colony formation assays, and in vivo xenograft models. Mechanistically, the mRNA and protein levels of DKK-1, a Wnt antagonist, were downregulated by CTTN. Treatment of the β-catenin/TCF inhibitor reversed CTTN-induced cancer stem cell-like properties in vitro. Combination treatment with trastuzumab and β-catenin/TCF inhibitor overcame trastuzumab resistance conferred by CTTN overexpression in in vitro colony formation assays.

Conclusions: CTTN activates DKK-1/Wnt/β-catenin signaling to induce trastuzumab resistance. We propose that CTTN is a novel biomarker indicating a poor prognosis and a possible therapeutic target for overcoming trastuzumab resistance.

Citing Articles

Tumour heterogeneity and personalized treatment screening based on single-cell transcriptomics.

Zhang X, Xie J, Yang Z, Yu C, Hu Y, Qin J Comput Struct Biotechnol J. 2025; 27:307-320.

PMID: 39877290 PMC: 11773088. DOI: 10.1016/j.csbj.2024.12.020.

DKK1 and Its Receptors in Esophageal Adenocarcinoma: A Promising Molecular Target.

Despotidis M, Lyros O, Driva T, Sarantis P, Kapetanakis E, Mylonakis A Diagnostics (Basel). 2025; 15(1.

PMID: 39795613 PMC: 11720708. DOI: 10.3390/diagnostics15010085.

YWHAG promotes colorectal cancer progression by regulating the CTTN-Wnt/β-catenin signaling axis.

Wang Y, Cao Y, Chen Y, Cheng H, Liu Z, Wang M Med Oncol. 2024; 41(5):100.

PMID: 38538804 DOI: 10.1007/s12032-024-02349-x.

Sinensetin suppresses breast cancer cell progression via Wnt/β-catenin pathway inhibition.

Zhu S, Meng L, Wei P, Gu G, Duan K Transl Cancer Res. 2024; 13(1):348-362.

PMID: 38410229 PMC: 10894327. DOI: 10.21037/tcr-23-1317.

Effects of Cortactin Expression on Prognosis in Patients with Breast Cancer.

Son H, Jee S, Cha H, Song K, Bang S, Kim H Diagnostics (Basel). 2023; 13(18).

PMID: 37761244 PMC: 10530131. DOI: 10.3390/diagnostics13182876.

References

Zaharieva B, Simon R, Diener P, Ackermann D, Maurer R, Alund G . High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol. 2003; 201(4):603-8. DOI: 10.1002/path.1481. View

Croker A, Allan A . Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med. 2008; 12(2):374-90. PMC: 3822530. DOI: 10.1111/j.1582-4934.2007.00211.x. View

Trapnell C, Hendrickson D, Sauvageau M, Goff L, Rinn J, Pachter L . Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol. 2012; 31(1):46-53. PMC: 3869392. DOI: 10.1038/nbt.2450. View

Ormandy C, Musgrove E, Hui R, Daly R, Sutherland R . Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat. 2003; 78(3):323-35. DOI: 10.1023/a:1023033708204. View

Chung S, Giehl N, Wu Y, Vadgama J . STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2013; 44(2):403-11. PMC: 3898805. DOI: 10.3892/ijo.2013.2195. View

Yu F, Zhao J, Hu Y, Zhou Y, Guo R, Bai J . The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo. Oncol Rep. 2016; 36(1):356-64. DOI: 10.3892/or.2016.4799. View

Ginestier C, Hur M, Charafe-Jauffret E, Monville F, Dutcher J, Brown M . ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2008; 1(5):555-67. PMC: 2423808. DOI: 10.1016/j.stem.2007.08.014. View

Uzair I, Conte Grand J, Flamini M, Sanchez A . Molecular Actions of Thyroid Hormone on Breast Cancer Cell Migration and Invasion via Cortactin/N-WASP. Front Endocrinol (Lausanne). 2019; 10:139. PMC: 6416158. DOI: 10.3389/fendo.2019.00139. View

Kim H, Choi H, Lee J, Kong G . Cancer Target Gene Screening: a web application for breast cancer target gene screening using multi-omics data analysis. Brief Bioinform. 2019; 21(2):663-675. DOI: 10.1093/bib/bbz003. View

10.

Choi H, Jin S, Cho H, Won H, An H, Jeong G . CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling. EMBO Rep. 2019; 20(10):e48058. PMC: 6776914. DOI: 10.15252/embr.201948058. View

11.

Derakhshani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati M . Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2019; 235(4):3142-3156. DOI: 10.1002/jcp.29216. View

12.

Wu Y, Ginther C, Kim J, Mosher N, Chung S, Slamon D . Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res. 2012; 10(12):1597-606. PMC: 3732195. DOI: 10.1158/1541-7786.MCR-12-0155-T. View

13.

Kim Y, Sung D, Oh E, Cho Y, Cho T, Farrand L . Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer. Cancer Lett. 2017; 412:118-130. DOI: 10.1016/j.canlet.2017.10.020. View

14.

Luo M, Shen X, Zhang Y, Wei F, Xu X, Cai Y . Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res. 2006; 66(24):11690-9. DOI: 10.1158/0008-5472.CAN-06-1484. View

15.

Nagini S . Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anticancer Agents Med Chem. 2016; 17(2):152-163. DOI: 10.2174/1871520616666160502122724. View

16.

Eke I, Deuse Y, Hehlgans S, Gurtner K, Krause M, Baumann M . β₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. J Clin Invest. 2012; 122(4):1529-40. PMC: 3314473. DOI: 10.1172/JCI61350. View

17.

Borg A, Sigurdsson H, Clark G, Ferno M, Fuqua S, Olsson H . Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer. 1991; 63(1):136-42. PMC: 1971653. DOI: 10.1038/bjc.1991.28. View

18.

Song K, Farzaneh M . Signaling pathways governing breast cancer stem cells behavior. Stem Cell Res Ther. 2021; 12(1):245. PMC: 8052733. DOI: 10.1186/s13287-021-02321-w. View

19.

Park H, Jee S, Son H, Cha H, Bang S, Kim H . Loss of Single-Stranded DNA Binding Protein 2 Expression Is Associated with Aggressiveness and Poor Overall Survival in Patients with Invasive Breast Carcinoma. Diagnostics (Basel). 2022; 12(2). PMC: 8871390. DOI: 10.3390/diagnostics12020487. View

20.

Schuuring E . The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes--a review. Gene. 1995; 159(1):83-96. DOI: 10.1016/0378-1119(94)00562-7. View